CorMedix Appoints Ernst & Young as New Auditor Amidst Existing Internal Control Weakness
CRMD sits 23% above its 52-week low of $6.125.
Summary
CorMedix Inc. has appointed Ernst & Young LLP as its new independent registered public accounting firm, replacing CBIZ CPAs P.C., with no reported disagreements with the outgoing firm despite a previously disclosed material weakness in internal controls.
Key Events · Corporate Governance and Compliance · CRMD
-
Auditor Dismissal
CorMedix dismissed CBIZ CPAs P.C. as its independent registered public accounting firm on June 25, 2026.
-
No Disagreements Reported
The company stated there were no disagreements with CBIZ CPAs on accounting principles, financial disclosure, or auditing scope.
-
Material Weakness Acknowledged
The dismissal occurred while a previously disclosed material weakness in internal control over financial reporting, related to reviewing significant non-routine transactions, remains.
-
New Auditor Appointed
Ernst & Young LLP (EY) has been appointed as the new independent registered public accounting firm for the fiscal year ending December 31, 2026.
Analysis · CRMD · Life Sciences
This 8-K reports a change in CorMedix's independent auditor. While the company explicitly stated there were no disagreements with the outgoing firm, CBIZ CPAs, the change occurs in the context of a previously disclosed material weakness in internal controls. The appointment of Ernst & Young, a major accounting firm, could be seen as a step towards addressing these control issues and enhancing audit quality, but the underlying weakness remains a point of attention.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRMD was trading at $7.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $615.8M. The 52-week trading range was $6.13 to $14.96. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.